Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) EBIT: ¥-266.9 Mil (TTM As of Mar. 2026)

What is Zhejiang Shapuaisi Pharmaceutical Co EBIT?

Zhejiang Shapuaisi Pharmaceutical Co SHSE:603168 -2.48% 37 EBIT is ¥-266.9 Mil as of Mar. 2026. GuruFocus rates SHSE:603168 with a GF Score™ of 37/100 and a GF Value™ of ¥8.52 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Zhejiang Shapuaisi Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥-24.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-266.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zhejiang Shapuaisi Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 was 1.63%. Zhejiang Shapuaisi Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -12.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zhejiang Shapuaisi Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -13.64%.

Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zhejiang Shapuaisi Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	27.224 * ( 1 - 0% )	/	( (1704.331	+	1645.966)	/ 2 )
=	27.224	/	1675.1485
=	1.63 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1872.251	-	191.032	-	( 224.399	-	max(0, 391.295	-	368.183	+	224.399	))
=	1704.331

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1771.048	-	159.902	-	( 121.026	-	max(0, 318.491	-	283.671	+	121.026	))
=	1645.966

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Zhejiang Shapuaisi Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-95.804	/	( ( (801.418 + max(-94.011, 0))	+	(788.887 + max(-35.401, 0)) )	/	2 )
=	-95.804	/	( ( 801.418	+	788.887 )	/	2 )
=	-95.804	/	795.1525
=	-12.05 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(26.651	+	76.721	+	16.027)	-	(191.032	+	0	+	22.378)
=	-94.011

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(26.739	+	87.589	+	22.875)	-	(159.902	+	0	+	12.702)
=	-35.401

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zhejiang Shapuaisi Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-266.861	/	1956.610
	=	-13.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Shapuaisi Pharmaceutical Co EBIT Related Terms

Zhejiang Shapuaisi Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for Zhejiang Shapuaisi Pharmaceutical Co's EBIT can be seen below:

Zhejiang Shapuaisi Pharmaceutical Co EBIT Chart

Zhejiang Shapuaisi Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

49.64

55.66

35.68

-108.93

-231.99

Zhejiang Shapuaisi Pharmaceutical Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															10.92	14.82	5.57	-263.30	-23.95

SHSE:603168 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Shapuaisi Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhejiang Shapuaisi Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Shapuaisi Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zhejiang Shapuaisi Pharmaceutical Co's EV-to-EBIT falls into.

Save Embed

37GF Score

Zhejiang Shapuaisi Pharmaceutical Co Ltd SHSE:603168

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Zhejiang Shapuaisi Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-266.9 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of ¥-266.9 Mil mean?

Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) has a EBIT of ¥-266.9 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zhejiang Shapuaisi Pharmaceutical Co.

Is Zhejiang Shapuaisi Pharmaceutical Co's EBIT too high?

Zhejiang Shapuaisi Pharmaceutical Co's current EBIT is ¥-266.9 Mil. Overall, Zhejiang Shapuaisi Pharmaceutical Co has a GF Score™ of 37/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Zhejiang Shapuaisi Pharmaceutical Co's EBIT compare to ZTS and UTHR?

Zhejiang Shapuaisi Pharmaceutical Co's EBIT of ¥-266.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zhejiang Shapuaisi Pharmaceutical Co. Zhejiang Shapuaisi Pharmaceutical Co's current EBIT is ¥-266.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Zhejiang Shapuaisi Pharmaceutical Co stock overvalued right now?

Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥8.52, compared to a current price of ¥4.72 — trading 44.6% below its estimated fair value. The current EBIT is ¥-266.9 Mil. Zhejiang Shapuaisi Pharmaceutical Co's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168), the current EBIT is ¥-266.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥4.72 is trading 44.6% below its estimated GF Value™ of ¥8.52. GuruFocus considers Zhejiang Shapuaisi Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for SHSE:603168:

EBIT: ¥-266.9 Mil
GF Value™: ¥8.52 vs. price of ¥4.72 (44.6% below fair value)
GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Shapuaisi Pharmaceutical Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SZSE:002817 SZSE:301130 SHSE:600080 SHSE:688189 BJSE:920017 SZSE:300519 SZSE:000590 SZSE:002581 SZSE:300254 SHSE:605199 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address No. 1588 Xinming Road, Economic Development Zone, Zhejiang Province, Pinghu, CHN, 314200

Website https://www.zjspas.com

Zhejiang Shapuaisi Pharmaceutical Co Ltd is a China based pharmaceutical company. It is engaged in drug research and development, production and operation. The product portfolio of the company includes oral solutions, eye drops, tablets, hard capsules, suppositories, granules, raw materials dosage forms such as medicines, rinsing agent and mixture, and others. The company operates pharmaceutical manufacturing companies, pharmaceutical sales company, pharmaceutical retail company and pharmaceutical research institute. The products offered by the company are sold in China and are also exported to the other countries.

37GF Score

Get the complete analysis for SHSE:603168

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.72

Price

¥8.52

GF Value

View SHSE:603168 Analysis

See EBIT data for all stocks →